Clinical Trial Update: Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing 30 mg/month versus 90 mg/month pamidronate prophylaxis in multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pamidronate disodium (Pamidronate disodium)

Snippet

Sponsor: Nordic Myeloma Study Group | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED